AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24281134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study 24281134 — intervention group
Group type: EXPERIMENTAL
Intervention: All variables (including 37 clinical characteristics)
Number of subjects: 2033
Study 24281134 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified model (using 8 items)
Number of subjects: 2033
Study 22554123 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange roughy oil
Number of subjects: 46
Study 22554123 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (Vaseline)
Number of subjects: 46
Study 22554123 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 46
Study 20919777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavalier humor beliefs (CHB)
Number of subjects: 0
Study 20919777 — intervention group
Group type: EXPERIMENTAL
Intervention: Jokes targeting low-status outgroup (Mexicans)
Number of subjects: 0
Study 20919777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest-posttest design
Number of subjects: 0
Study 18393056 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling
Number of subjects: 452
Study 18393056 — intervention group
Group type: COMPARATOR
Intervention: Substance use/conduct disorder
Number of subjects: 452
Study 18393056 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling preferences/frequency
Number of subjects: 452
Study 16080909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra) 100 mg
Number of subjects: 15
Study 16080909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11923794 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin 1.0 mg/kg bolus followed by a 4-hour infusion at 2.5 mg/kg/h
Number of subjects: 42
Study 11923794 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin 0.75 mg/kg bolus followed by a 4-hour infusion at 1.75 mg/kg
Number of subjects: 42
Study 11923794 — intervention group
Group type: COMPARATOR
Intervention: Heparin 60 U/kg bolus
Number of subjects: 42
Study 11923794 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including bivalirudin and heparin) with eptifibatide
Number of subjects: 42
Study 11923794 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin and Heparin
Number of subjects: 42
Study 11923794 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 42
Study 10793302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed meal-replacement weight-control program (MR)
Number of subjects: 158
Study 10793302 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 158
Study 8780425 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric Research Interview for Substance and Mental Disorders (PRISM)
Number of subjects: 172
Study 1321858 — intervention group
Group type: COMPARATOR
Intervention: RRV (VP7 serotype 3)
Number of subjects: 223
Study 1321858 — intervention group
Group type: COMPARATOR
Intervention: DxRRV (VP7 serotype 1)
Number of subjects: 223
Study 6430326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 16
Study 6430326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30719861 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlutech Figulla Flex II occluder
Number of subjects: 0
Study 30719861 — intervention group
Group type: COMPARATOR
Intervention: Amplatzer Septal Occluder
Number of subjects: 0
Study 29178495 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450-nm diode laser (DL)
Number of subjects: 25
Study 29178495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional microneedling radiofrequency (FMR)
Number of subjects: 25
Study 26762374 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol enriched soy-based yogurts (4.0 g plant stanols/d)
Number of subjects: 58
Study 26762374 — intervention group
Group type: COMPARATOR
Intervention: Control soy-based yogurt without added plant stanol esters
Number of subjects: 58
Study 24447074 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low glucose management (PLGM) system
Number of subjects: 22
Study 24447074 — intervention group
Group type: COMPARATOR
Intervention: Low glucose suspend (LGS)
Number of subjects: 22
Study 23180952 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to triple therapy
Number of subjects: 234
Study 23180952 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks after triple therapy
Number of subjects: 234
Study 23180952 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (omeprazole 20 mg bid, clarithromycin 500 mg bid, and amoxicillin 1000 mg bid)
Number of subjects: 234
Study 23180952 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to or after triple therapy
Number of subjects: 234
Study 23180952 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom relief
Number of subjects: 234
Study 19925528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine 10-20 mg once daily for 4 weeks
Number of subjects: 196
Study 19925528 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50-100 mg once daily for 4 weeks
Number of subjects: 196
Study 19925528 — intervention group
Group type: COMPARATOR
Intervention: Cilnidipine vs Losartan
Number of subjects: 196
Study 19925528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine and Losartan
Number of subjects: 196
Study 19034343 — intervention group
Group type: EXPERIMENTAL
Intervention: External shielding of the testis during pelvic radiotherapy
Number of subjects: 19
Study 19034343 — intervention group
Group type: COMPARATOR
Intervention: No external shielding of the testis during pelvic radiotherapy
Number of subjects: 19
Study 19034343 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom measurements
Number of subjects: 19
Study 28025969 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (valsartan tablet)
Number of subjects: 18
Study 28025969 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (valsartan tablet)
Number of subjects: 18
Study 11140029 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency-based primary care drug therapy (PCDT) training programme
Number of subjects: 66
Study 11140029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 66
Study 9270083 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker (terazosin)
Number of subjects: 45
Study 8296255 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 26
Study 8296255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3325318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline capsules
Number of subjects: 30
Study 3325318 — intervention group
Group type: COMPARATOR
Intervention: Standard slow-release theophylline tablets
Number of subjects: 30
Study 2584664 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 26
Study 2584664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31087650 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stage diagnosis (stages I and II)
Number of subjects: 2311
Study 31087650 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced stage diagnosis (stages III and IV)
Number of subjects: 2311
Study 31087650 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2311
Study 31087650 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients diagnosed in late stages
Number of subjects: 2311
Study 31087650 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-specific survival
Number of subjects: 2311
Study 31087650 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 2311
Study 31302440 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial Direct Current Stimulation)
Number of subjects: 22
Study 31302440 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS (Transcranial Magnetic Stimulation)
Number of subjects: 22
Study 31302440 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (Electroconvulsive Therapy)
Number of subjects: 22
Study 31302440 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NIBS studies
Number of subjects: 22
Study 27714649 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered stepped collaborative care (CC)
Number of subjects: 329
Study 27714649 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 329
Study 26003546 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 26003546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study 26003546 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and Mediterranean diet (combined)
Number of subjects: 0
Study 26003546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 23232039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI eFlow(®) rapid nebuliser
Number of subjects: 27
Study 23232039 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI LC Plus(®) nebuliser
Number of subjects: 27
Study 23232039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution 300 mg/4 mL (TNS4)
Number of subjects: 27
Study 21383098 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 150 mg maraviroc b.i.d. with darunavir-ritonavir
Number of subjects: 0
Study 21383098 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 300 mg maraviroc b.i.d. with etravirine
Number of subjects: 0
Study 21383098 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 150 mg maraviroc b.i.d. with etravirine-darunavir-ritonavir
Number of subjects: 0
Study 21383098 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0
Study 21383098 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc with darunavir-ritonavir, etravirine, or both
Number of subjects: 0
Study 19246721 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 0
Study 19246721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16298542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy Logic Controller (FLC)
Number of subjects: 17
Study 16298542 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Organizing Fuzzy Logic Controller (SOFLC)
Number of subjects: 17
Study 16298542 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rule-Based Controller (RBC)
Number of subjects: 17
Study 15273033 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth nursing service
Number of subjects: 12
Study 11217680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761
Number of subjects: 19
Study 11217680 — intervention group
Group type: COMPARATOR
Intervention: Placebo or reference drugs
Number of subjects: 19
Study 9051392 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus BCAA supplement
Number of subjects: 24
Study 9051392 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus placebo
Number of subjects: 24
Study 9051392 — intervention group
Group type: COMPARATOR
Intervention: Sedentary plus BCAA supplement
Number of subjects: 24
Study 9051392 — intervention group
Group type: COMPARATOR
Intervention: Sedentary plus placebo
Number of subjects: 24
Study 9051392 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (overall)
Number of subjects: 24
Study 9051392 — intervention group
Group type: COMPARATOR
Intervention: BCAA supplementation
Number of subjects: 24
Study 8364776 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 300 mg 1 hour before each meal and at bedtime (n = 16)
Number of subjects: 42
Study 8364776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid (n = 12)
Number of subjects: 42
Study 8364776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.) plus metronidazole (250 mg t.i.d; n = 14)
Number of subjects: 42
Study 8364776 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 42
Study 3753801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms per kilogram of body weight, single oral dose)
Number of subjects: 0
Study 3753801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 3753801 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine or placebo
Number of subjects: 0
Study 29195025 — intervention group
Group type: EXPERIMENTAL
Intervention: CLM + BUD (clarithromycin 0.25 g/d and budesonide 256 μg/d)
Number of subjects: 74
Study 29195025 — intervention group
Group type: COMPARATOR
Intervention: BUD (budesonide 256 μg/d)
Number of subjects: 74
Study 29195025 — intervention group
Group type: EXPERIMENTAL
Intervention: CLM + BUD
Number of subjects: 74
Study 29195025 — intervention group
Group type: COMPARATOR
Intervention: BUD
Number of subjects: 74
Study 27601539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
Number of subjects: 0
Study 27601539 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and Dexamethasone (Rd)
Number of subjects: 0
Study 25175529 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exchange with roommates across 5 weeks
Number of subjects: 214
Study 25175529 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived similarity measured in the second week
Number of subjects: 214
Study 25175529 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exchange
Number of subjects: 214
Study 20850895 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 506
Study 20850895 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly
Number of subjects: 506
Study 20850895 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 506
Study 20850895 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (all dosages)
Number of subjects: 506
Study 20385988 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 1062
Study 20385988 — intervention group
Group type: COMPARATOR
Intervention: CHOP (without rituximab)
Number of subjects: 1062
Study 18241260 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 5.4 g daily (n = 21)
Number of subjects: 53
Study 18241260 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic control of saturated fatty acids (n = 23)
Number of subjects: 53
Study 15931018 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) intervention for 15 weeks, practicing techniques at home twice a day
Number of subjects: 95
Study 15931018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac education (EDU) program for 15 weeks
Number of subjects: 95
Study 15931018 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 95
Study 12881583 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIO-enhanced MR imaging
Number of subjects: 134
Study 12881583 — intervention group
Group type: COMPARATOR
Intervention: gadolinium-enhanced MR imaging
Number of subjects: 134
Study 11025833 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear peak clipper (PC) hearing aid circuit
Number of subjects: 360
Study 11025833 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression limiter (CL) hearing aid circuit
Number of subjects: 360
Study 11025833 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide dynamic range compressor (WDRC) hearing aid circuit
Number of subjects: 360
Study 11025833 — intervention group
Group type: COMPARATOR
Intervention: Aided conditions (all circuits)
Number of subjects: 360
Study 9069478 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H‐MRS) in patients with progressive supranuclear palsy
Number of subjects: 13
Study 9069478 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H‐MRS) in patients with idiopathic Parkinson's disease
Number of subjects: 13
Study 9069478 — intervention group
Group type: COMPARATOR
Intervention: Healthy age matched controls
Number of subjects: 13
Study 8347120 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal Training (bibliotherapy)
Number of subjects: 127
Study 8347120 — intervention group
Group type: COMPARATOR
Intervention: Urine device with specific instructions
Number of subjects: 127
Study 8347120 — intervention group
Group type: COMPARATOR
Intervention: Urine alarm only
Number of subjects: 127
Study 3558936 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded pulmonary-artery catheters
Number of subjects: 20
Study 3558936 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-bonded pulmonary-artery catheters
Number of subjects: 20
Study 31708063 — intervention group
Group type: EXPERIMENTAL
Intervention: Star rating-targeted medications (oral antidiabetic medications, RAS antagonists, statins)
Number of subjects: 1218104
Study 31708063 — intervention group
Group type: COMPARATOR
Intervention: Nontargeted antihypertensive and antihyperlipidemic medications
Number of subjects: 1218104
Study 29030894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg once-daily for 12 weeks
Number of subjects: 1703
Study 29030894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg once-daily for 12 weeks
Number of subjects: 1703
Study 29030894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1703
Study 25559252 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued-incentive condition receiving weekly incentives during fall semester 2011, and no incentives during spring semester 2012
Number of subjects: 117
Study 25559252 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued-incentive condition receiving weekly incentives during fall semester, and incentives on a variable-interval schedule during spring semester
Number of subjects: 117
Study 25559252 — intervention group
Group type: COMPARATOR
Intervention: Control condition receiving no incentives for meeting fitness‐center attendance goals
Number of subjects: 117
Study 23336578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (SES)
Number of subjects: 15934
Study 23336578 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking, alcohol use, not working outside the home
Number of subjects: 15934
Study 23336578 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides
Number of subjects: 15934
Study 23336578 — intervention group
Group type: EXPERIMENTAL
Intervention: High HbA1c
Number of subjects: 15934
Study 23336578 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised fasting glucose
Number of subjects: 15934
Study 23336578 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI
Number of subjects: 15934
Study 23336578 — intervention group
Group type: EXPERIMENTAL
Intervention: High waist circumference
Number of subjects: 15934
Study 21454845 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message (n = 158)
Number of subjects: 318
Study 21454845 — intervention group
Group type: COMPARATOR
Intervention: Voice message (n = 160)
Number of subjects: 318
Study 18377687 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 33
Study 18377687 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 33
Study 18377687 — intervention group
Group type: COMPARATOR
Intervention: sweetness matched placebo drink
Number of subjects: 33
Study 18377687 — intervention group
Group type: EXPERIMENTAL
Intervention: blood glucose concentration
Number of subjects: 33
Study 16563170 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery (CABG)
Number of subjects: 561
Study 16563170 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard on-pump CABG
Number of subjects: 561
Study 16563170 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 561
Study 16563170 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D
Number of subjects: 561
Study 16563170 — intervention group
Group type: COMPARATOR
Intervention: SF-6D
Number of subjects: 561
Study 14585893 — intervention group
Group type: EXPERIMENTAL
Intervention: Spindle-aligned microinjection
Number of subjects: 246
Study 14585893 — intervention group
Group type: COMPARATOR
Intervention: PB-aligned control group
Number of subjects: 246
Study 11063177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 100
Study 11063177 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (2.5 mg)
Number of subjects: 100
Study 11063177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11063177 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100
Study 8891015 — intervention group
Group type: EXPERIMENTAL
Intervention: Micanol (dithranol micro-encapsulated in crystalline monoglycerides)
Number of subjects: 8
Study 8891015 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB therapy
Number of subjects: 8
Study 8891015 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Micanol and UVB therapy
Number of subjects: 8
Study 8891015 — intervention group
Group type: COMPARATOR
Intervention: Dithranol treatment (previous studies)
Number of subjects: 8
Study 2000823 — intervention group
Group type: COMPARATOR
Intervention: 0 mg beta-carotene/d
Number of subjects: 50
Study 2000823 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg beta-carotene/d
Number of subjects: 50
Study 2000823 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg beta-carotene/d
Number of subjects: 50
Study 2000823 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg beta-carotene/d
Number of subjects: 50
Study 2000823 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg beta-carotene/d
Number of subjects: 50
Study 6655232 — intervention group
Group type: EXPERIMENTAL
Intervention: smoking under no stress
Number of subjects: 51